Molecular subtypes of breast cancers and treatment options outside of traditional surgery and radiotherapy [5–10]
| Subtype | Molecular characteristics | Approximate incidence | Treatment options |
|---|---|---|---|
| Luminal A-like | ER+, PR±, HER2–Low Ki-67Lower grade | 60–70% | Endocrine therapyTargeted therapyChemotherapy |
| Luminal B-like HER2– | ER+, PR±, HER2–High Ki-67Higher grade | 10–20% | Endocrine therapyTargeted therapyChemotherapy |
| Luminal B-like HER2+ | ER+, PR±, HER2+High Ki-67Higher grade | 13–15% | Endocrine therapyTargeted therapyChemotherapy |
| HER2-enriched (non-luminal) | ER–, PR–, HER2+High Ki-67Higher grade | ChemotherapyTargeted therapy | |
| Triple-negative | ER–, PR–, HER2–High Ki-67Higher grade | 10–15% | ChemotherapyTargeted therapyImmunotherapy |
All authors contributed to the conception and design of the article, writing of the first draft of the manuscript, reading and approval of the submitted version. EYL and DCS revised the manuscript in response to reviewers comments.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Funding support was received from the Auckland Medical Research Foundation grant 1120013 (GJC); Cancer Society Auckland Northland (DCS); and Breast Cancer Foundation NZ grant R1902 (DCS, EYL). The funders had no role in the study design, in the collection, analysis, and interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication.
© The Author(s) 2022.